Merck KGaA (OTCMKTS:MKKGY – Get Free Report)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $27.86, but opened at $29.24. Merck KGaA shares last traded at $29.1570, with a volume of 814 shares trading hands.
Analyst Ratings Changes
Several equities analysts recently commented on the company. Sanford C. Bernstein raised Merck KGaA to a “hold” rating in a report on Thursday, March 19th. Deutsche Bank Aktiengesellschaft lowered Merck KGaA from a “buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Four research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Merck KGaA presently has a consensus rating of “Hold”.
Check Out Our Latest Stock Analysis on MKKGY
Merck KGaA Stock Performance
Merck KGaA (OTCMKTS:MKKGY – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.14. The company had revenue of $6.03 billion for the quarter, compared to analyst estimates of $5.93 billion. Merck KGaA had a return on equity of 8.93% and a net margin of 12.07%. On average, research analysts forecast that Merck KGaA will post 1.83 EPS for the current fiscal year.
Merck KGaA Company Profile
Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.
Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.
Further Reading
- Five stocks we like better than Merck KGaA
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
- 2 Software Stocks Turning AI Fears Into Fundamental Gains
- The Token Takeover: SEC Triggers Market Quake
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
